Indeed both, GLP‐1 receptor agonists and DPP‐IV inhibitors were shown to induce beta‐cell proliferation and reverse new‐onset diabetes.27, 28, 29 Still, in individuals with type 1 DM, treatment with GLP‐1 receptor agonist or DPP‐IV inhibitors yielded more heterogeneous results with some studies showing a beneficial effect on glucose control and other with no effect at all.30 There may be several reasons why results from animal models of type 1 DM and people with type 2 DM do not convincingly translate to individuals with type 1 DM. The gene discussed is GLP1R; the disease is diabetes mellitus.